ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Study in Solid Tumor
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Ono Pharmaceutical
- 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jan 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Oct 2014 New trial record